Distribution of Abatement Funds Arising From US Opioid Litigation

G Caleb Alexander; Omar Mansour

doi:10.1001/jama.2022.19667

Distribution of Abatement Funds Arising From US Opioid Litigation

JAMA. 2022 Nov 15;328(19):1901-1902. doi: 10.1001/jama.2022.19667.

Authors

G Caleb Alexander^{1

2}, Omar Mansour³

Affiliations

¹ Center for Drug Safety and Effectiveness, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
² Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
³ Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.

PMID: 36306147
DOI: 10.1001/jama.2022.19667

No abstract available

Plain language summary

This Viewpoint discusses the settlement agreements reached against several major pharmaceutical distributors resulting from the US opioid epidemic and how those funds will be distributed amongst the states.

MeSH terms

Analgesics, Opioid* / adverse effects
Analgesics, Opioid* / economics
Compensation and Redress* / legislation & jurisprudence
Drug Industry* / economics
Drug Industry* / legislation & jurisprudence
Humans
Legislation, Drug / economics
Opioid-Related Disorders* / economics
Opioid-Related Disorders* / prevention & control
Tobacco Industry
United States

Substances

Analgesics, Opioid